Unlocking New Cancer Immunotherapy Potential: How TCR-pMHC Recognition Triggers T Cell Phagocytosis Through Mechanobiology

A groundbreaking study recently published in Mechanobiology in Medicine has unveiled a revolutionary function of T cells, transforming our understanding of their role in immune defense. By demonstrating that CD8+ T cells, upon specific antigen recognition, can perform phagocytosis—a mechanism traditionally restricted to professional phagocytes—this work challenges the long-standing paradigm that T cells merely orchestrate immune responses rather than directly engulfing pathogenic targets. Utilizing advanced micromanipulation techniques, researchers engineered Jurkat T cells to express an optimized T cell receptor (TCR) with high affinity for a SARS-CoV-2 derived epitope. This enabled real-time visualization and manipulation of TCR-peptide-MHC (pMHC) interactions, revealing previously unappreciated phagocytic capabilities triggered by highly specific antigen engagement.

At the heart of this discovery lies the lentiviral transduction of CD8+ Jurkat T cells with SVAR16, a human TCR exhibiting intermediate-to-high two-dimensional (2D) affinity for the SARS-CoV-2 epitope presented by HLA-A2:01 complexed with the YLQ peptide. This precise molecular modification allowed these engineered T cells to engage pMHC-coated microbeads mimicking antigen-presenting targets. Employing the Biomembrane Force Probe (BFP), an exquisite tool for quantifying nanoscale forces during immune synapse formation, investigators controlled the duration and strength of engagement between TCRs and their cognate antigens tethered on bead surfaces. This precise control was pivotal to uncovering the rapid sequence of events culminating in phagosome formation and bead engulfment, documented over a matter of minutes.

The kinetics of T cell-bead interaction were particularly striking. Upon contact with beads coated with cognate pMHC molecules, T cells rapidly formed tight conjugates within seconds. This was followed by the initiation of phagosome formation within minutes and culminated in the complete internalization of the beads around four minutes after initial contact. These kinetics were remarkably consistent across multiple experimental replicates, reinforcing the robustness of this newly described phenomenon. Notably, when control beads presenting an irrelevant pMHC complex (HLA-A2:01–SL9 from HIV Gag) were used, T cells failed to form conjugates or engage in phagocytosis even after extended incubation times, confirming the strict antigen specificity of this process.

Intriguingly, all SVAR16-transduced T cell lines tested were capable of initiating phagosome formation rapidly, with approximately half achieving complete engulfment of the beads. These results underscore a critical mechanistic insight: the co-engagement of TCRs with their specific antigenic pMHC ligands, supported by CD8 coreceptors, is both necessary and sufficient to drive phagocytic activity in T cells. This implies that TCR-mediated recognition does not merely trigger cytotoxic and signaling pathways but can directly orchestrate cytoskeletal rearrangements and membrane remodeling traditionally associated with classical phagocytes like macrophages and dendritic cells.

Delving deeper into the mechanistic underpinnings, the study elegantly demonstrates that phagocytic efficacy is tightly regulated by the density of antigenic sites presented on the target surface. By precisely tuning the site density of pMHC molecules displayed on the microbeads—from high densities of over 1200 molecules per square micrometer down to as low as 27 molecules per square micrometer—researchers observed a marked decline in the proportion of T cells initiating phagocytosis, the delay in phagosome formation, and the outright failure of full phagocytic uptake at the lowest antigen densities. This indicates a stringent threshold of TCR-pMHC engagement required for triggering the energetically costly and coordinated process of phagocytosis within T cells.

From a signaling perspective, these events link tightly to canonical T cell activation pathways known to regulate actin cytoskeletal dynamics. Activation of the LAT–SLP-76–Vav1 signaling complex downstream of TCR engagement leads to the activation of Rho family GTPases, which orchestrate actin polymerization necessary for extending pseudopods around the target particle. Simultaneously, intracellular calcium fluxes—a hallmark of T cell activation—play a key role in modulating cytoskeletal rearrangement and vesicle trafficking to facilitate phagosome maturation. This finely tuned integration of biochemical signaling cascades and biophysical forces underpins the unprecedented capacity of T cells to physically engulf antigen-presenting surfaces.

Mechanobiological analyses revealed that the phagocytic process imposes dynamic mechanical stresses on the TCR-pMHC bonds. Initial recognition involves a sparse set of TCR-pMHC interactions that must sustain mechanical loads while the T cell begins to extend membrane protrusions. As pseudopods enlarge contact areas with the bead, mechanical load distribution shifts across multiple bonds, creating a dynamically fluctuating force landscape within the immunological synapse. This mechanoregulated signaling likely optimizes T cell responsiveness and may serve as a design principle for enhancing engineered T cell therapies by selecting TCRs or chimeric antigen receptors (CARs) with superior two-dimensional affinities and catch-bond behaviors to endure the shear and compressive forces found in solid tumor microenvironments.

The translational implications of these findings for cancer immunotherapy are profound. While CD8+ cytotoxic T cells have been the primary focus for direct tumor cell killing, this study suggests that equipping CD4+ T helper cells with phagocytic functions could provide a new axis of potent antitumor activity. Phagocytic T cells could not only directly remove antigen-positive tumor cells but also modulate the tumor microenvironment by clearing antigens that drive T cell exhaustion or by shaping the phenotype of neighboring immune cells. This approach could augment immune infiltration, enhance local immune activation, and address the persistent challenge of solid tumors, which remain resistant to many current immunotherapeutic strategies.

The discovery also provides a novel framework for the rational design of engineered T cell therapies. By tuning the biochemical affinity and mechanophysical properties of the TCR-pMHC interface, it may be possible to optimize phagocytic efficiency and sustain signaling under adverse mechanical conditions characteristic of tumors. Such mechanobiological optimization could overcome limitations inherent to existing CAR-T therapies, enabling engineered T cells to perform functions beyond cytotoxicity, including direct physical clearance of tumor cells and modulation of the immune milieu.

Looking ahead, the researchers emphasize the importance of validating and translating these findings to more physiologically relevant systems. While Jurkat T cells serve as a valuable model for dissecting signaling pathways, primary human CD4+ T cells differ notably in activation thresholds, metabolic programming, and membrane mechanical properties. Future studies will focus on engineering primary human T cells with class I-restricted TCRs or CARs to fully characterize phagocytic mechanisms across diverse T cell subsets and activation states. Additionally, targeted manipulation of key signaling nodes such as LAT–SLP-76–Vav1 complexes and intracellular calcium flux, combined with mechanobiological engineering of receptor properties, will be essential steps toward clinical application.

This paradigm-shifting research not only redefines functional boundaries within T cell biology but also opens exciting avenues for future immunotherapy development. By harnessing the intrinsic phagocytic capacity of T cells through antigen-specific receptor engagement, scientists can envision next-generation immune cell therapies capable of multifaceted tumor eradication. The convergence of molecular immunology, cell biology, and biophysical engineering heralds a new era where T cells are not merely sentinels but active phagocytic agents of immune defense, poised to tackle diseases ranging from viral infections to solid malignancies with unprecedented efficacy.